Physician profile
Robert S Davis
NPI 1164473146
$4,839.58
in general payments reported to CMS, 2019-2025
28 companies · $32.80 in 2025
The $32.80 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $771 · 2020: $491 · 2021: $989 · 2022: $975 · 2023: $1,135 · 2024: $447 · 2025: $32.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,514.65 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,065.15 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Mallinckrodt Hospital Products INC. | $704.15 | 2020-2025 | Acthar |
| Actelion Pharmaceuticals US, INC. | $668.07 | 2019-2024 | Uptravi, Opsumit |
| Paratek Pharmaceuticals, INC. | $512.37 | 2021-2024 | Nuzyra |
| Mylan Specialty L.P. | $255.20 | 2019-2023 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $212.46 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.90 | 2021-2024 | Ofev |
| Astrazeneca Pharmaceuticals Lp | $168.29 | 2019-2024 | Airsupra, Breztri |
| Mallinckrodt Enterprises LLC | $159.42 | 2019 | |
| Sunovion Pharmaceuticals INC. | $132.69 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $110.48 | 2023 | Purified Cortrophin Gel |
| Resmed Corp | $89.58 | 2019-2024 | |
| Daiichi Sankyo INC. | $85.12 | 2021-2022 | |
| Advanced Respiratory, INC | $81.40 | 2019-2021 | |
| Axsome Therapeutics, INC. | $56.51 | 2023 | Sunosi |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $48.02 | 2024 | Inspire |
| Genzyme Corporation | $45.51 | 2019-2023 | |
| Grifols USA, LLC | $38.71 | 2022-2024 | Prolastin-C Liquid |
| Merck Sharp & Dohme LLC | $36.65 | 2019-2023 | Dificid, Zerbaxa |
| Jazz Pharmaceuticals INC. | $35.89 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $35.07 | 2022-2023 | Airduo Digihaler |
| Novartis Pharmaceuticals Corporation | $23.87 | 2019 | |
| Shire North American Group INC | $23.41 | 2019 | |
| Baxter Healthcare | $18.23 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.24 | 2021 | |
| Genentech USA, INC. | $16.18 | 2019 | |
| Philips North America LLC | $13.89 | 2019 | |
| Circassia INC. | $11.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.